3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
4
Metastatic Castration-resistant Prostate Cancer
2
Breast Neoplasms
2
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Fanconi Anemia, Complementation Group D1
1
Endometrial Neoplasms
1
Interventions
olaparib
1
cc-486
1
Azacitidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Pathologic Complete Response
×
olaparib
×
Clear all
NCT01844986
2025-12-10
SOLO-1
AstraZeneca
Phase 3
Active not recruiting
450 enrolled
18 charts
1 FDA